ondansetron has been researched along with Hypertension, Portal in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tripkovic, M | 1 |
| Kozjek, F | 1 |
| Krizman, I | 1 |
| Jereb, J | 1 |
| Francetic, I | 1 |
| Grabnar, I | 1 |
| Mrhar, A | 1 |
1 trial available for ondansetron and Hypertension, Portal
| Article | Year |
|---|---|
Effects of ondansetron on portal hemodynamics in liver cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Double-Blind Method; Female; Hemodynamics; Humans; Hyperte | 2000 |